DNA Blood Test Detects Cancer Resistance Using Inostics
1 Page
English
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

DNA Blood Test Detects Cancer Resistance Using Inostics' BEAMing Technology

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer
1 Page
English

Description

DNA Blood Test Detects Cancer Resistance Using Inostics' BEAMing Technology PR Newswire BALTIMORE, Maryland and HAMBURG, Germany, June 18, 2012 BALTIMORE, Maryland and HAMBURG, Germany, June 18, 2012 /PRNewswire

Subjects

Informations

Published by
Reads 14
Language English

Exrait

DNA Blood Test Detects Cancer Resistance
Using Inostics' BEAMing Technology
PR Newswire
BALTIMORE, Maryland and HAMBURG, Germany, June 18, 2012
BALTIMORE, Maryland
and
HAMBURG, Germany
,
June 18, 2012
/PRNewswire/ --
Two studies published back-to-back in last week's
Nature
applied DNA blood
testing using the BEAMing technology to detect drug resistance mediated by
KRAS mutations in colorectal cancer patients months before treatment failure
was observed.
The group led by Alberto Bardelli, PhD of the University of
Torino, Italy
describes the development of secondary resistance mutations to the anti-EGFR
monoclonal antibody cetuximab (Erbitux®) in patients with metastatic
colorectal cancer (mCRC) [Misale S.
et al.,
Nature Epub
13 June 2012
]
.
The
second group led by Luis Diaz, MD and Bert Vogelstein, MD from Johns Hopkins
University reached similar conclusions after studying mCRC patients treated
with a monotherapy of panitumumab (Vectibix®) [Diaz Jr LA
et al.,
Nature Epub
13 June 2012
].
Both teams concluded that blood-based noninvasive monitoring of patients
undergoing targeted therapy could provide significant benefits by allowing for
early intervention with additional treatment options that may delay or prevent
disease progression.
The BEAMing technology is a combination of digital PCR and flow cytometry
originally developed by the group of Bert Vogelstein, MD. Inostics licensed the
technology from the Johns Hopkins University and automated it for routine use.
BEAMing is the most sensitive and quantitative technology available today for
the detection of tumor specific somatic mutations in blood samples. Inostics'
BEAMing services are readily available to support clinical trials and research in
oncology. Furthermore, Inostics will offer BEAMing as a CLIA certified test for
routine analysis.
For more information on blood testing and the BEAMing Digital PCR technology
refer to http://www.inostics.com or email us at info@inostics.com.
Please contact:
Inostics
Friederike Lehmann, PhD
Marketing & Licensing
Phone +49(0)40-413383-90
Fax
+49(0)40-413383-99
lehmann@inostics.com
http://www.inostics.com